 |
| | AGENDA |
| | . |
| 12:30 – 1:30 | Registration & Networking
|
| 1:30 – 1:40 | Welcome and Opening Remarks
Phil Greenberg, Head of the Program in Immunology and member of the Clinical Research Division, Fred Hutch; Professor of Medicine/Oncology and of Immunology, University of Washington
Jim Edwards, Publisher, Xconomy |
| 1:40 – 2:10 | Can CAR-T Be Tamed?
Hans Bishop, CEO, Juno Therapeutics
Richard Maziarz, Medical Director, Adult Blood and Marrow Stem Cell Transplant Program, Oregon Health and Science University
Alex Lash, National Biotechnology Editor, Xconomy (moderator)
|
| 2:10 – 2:40 | Chasing Cancer Vaccines
Andrew Allen, CEO, Gritstone Oncology
Jay Venkatesan, President, Alpine Immune Sciences
Alex Lash, National Biotechnology Editor, Xconomy (moderator) |
| 2:40 – 3:10 | Teaming Up On Immunotherapy’s Frontier
Jill O’Donnell-Tormey, CEO, Cancer Research Institute
Ilya Shmulevich, Professor, Institute for Systems Biology
Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Company
Andrew Albertson, Partner, Fenwick & West (moderator) |
| 3:10 – 3:40 | Networking Break |
| 3:40– 4:05 | Kids, Cancer Care, and Lessons Learned
Michael Jensen, MD, Director, Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute |
| 4:05 – 4:35 | Deciphering The Immune System
Brad Gray, CEO, NanoString Technologies
Chad Robins, President & CEO, Adaptive Biotechnologies
Alex Lash, National Biotechnology Editor, Xconomy (moderator) |
| 4:35 – 5:05 | T Cell Treatments Under The Radar
Maria Fardis, CEO, Lion Biotechnologies
Sylvia Lee, Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center |
| 5:05 – 5:30 | How Lung Cancer Became Immunotherapy’s Biggest Success
Renato Martins, Medical Director, Thoracic/Head and Neck Oncology, University of Washington School of Medicine |
| 5:30 – 6:30 | Networking Reception |
